Paraneoplastyczne zespoły nerwowe – Rokowania, prognozy i postęp choroby

Paraneoplastyczne zespoły nerwowe
Rokowania, prognozy i postęp choroby

Paraneoplastyczne zespoły nerwowe (PNS) stanowią rzadką, ale klinicznie istotną grupę schorzeń, które rozwijają się w przebiegu nowotworów, wynikając z autoimmunologicznego ataku układu odpornościowego na struktury OUN, obwodowy układ nerwowy lub mięśnie. Rokowanie w PNS jest zróżnicowane i zależy od typu oraz zaawansowania nowotworu podstawowego, a także od rodzaju zespołu paraneoplastycznego – np. rozsiane wykrzepianie wewnątrznaczyniowe wiąże się z niekorzystnym przebiegiem, podczas gdy osteoartropatia przerostowa może sugerować lepszą prognozę. W badaniach długoterminowych, w okresie do 8 lat obserwacji, nie stwierdzono istotnej różnicy w śmiertelności u pacjentów z PNS w porównaniu do chorych bez tych zespołów, z wyjątkiem pacjentów z zespołem miastenicznym Lamberta-Eatona (LEMS) i drobnokomórkowym rakiem płuca (SCLC), u których mediana całkowitego przeżycia wynosiła 17 miesięcy w porównaniu do 7 miesięcy u pacjentów z samym SCLC (P=0,0001).

Prognoza paraneoplastycznych zespołów nerwowych

Czynniki wpływające na rokowanie
Rezultaty długoterminowe
Przyczyny zgonów
Wpływ leczenia na rokowanie
Jakość życia pacjentów
Znaczenie wczesnej diagnostyki
Kolejne rozdziały

Prognoza paraneoplastycznych zespołów nerwowych

Paraneoplastyczne zespoły nerwowe to rzadka grupa schorzeń, która rozwija się u niektórych osób chorujących na nowotwory. Występują, gdy komórki układu odpornościowego, zwalczające nowotwór, atakują również zdrowe części mózgu, rdzenia kręgowego, nerwów obwodowych lub mięśni. Prognoza w przypadku tych zespołów jest zróżnicowana i zależy od wielu czynników.¹²

Czynniki wpływające na rokowanie

Paraneoplastyczne zespoły nerwowe różnią się znacznie między pacjentami, co powoduje, że rokowanie może być bardzo zróżnicowane. Na przykład, rozsiane wykrzepianie wewnątrznaczyniowe wskazuje na złe rokowanie, podczas gdy osteoartropatia przerostowa jest jednym z niewielu zespołów paraneoplastycznych, które mogą sugerować korzystniejszą prognozę.³

Wczesne rozpoznanie i odpowiednia opieka są kluczowe dla leczenia nowotworu i zapobiegania dalszym uszkodzeniom układu nerwowego. Opóźniona diagnoza może wpływać na chorobowość, ale dokładny wpływ czasu rozpoznania na ostateczne wyniki nie jest w pełni poznany.⁴⁵

Rezultaty długoterminowe

Badania długoterminowe wykazują, że przeżywalność pacjentów z paraneoplastycznymi zespołami nerwowymi zależy przede wszystkim od rodzaju i stopnia zaawansowania nowotworu podstawowego. W obserwacji trwającej do 8 lat nie wykazano różnicy w śmiertelności wśród pacjentów, którzy początkowo prezentowali objawy paraneoplastycznych zespołów nerwowych.⁶

W szczególnych przypadkach, takich jak zespół miasteniczny Lamberta-Eatona (LEMS), pacjenci z drobnokomórkowym rakiem płuca (SCLC) i LEMS wykazują znacząco dłuższe przeżycie w porównaniu do pacjentów z samym SCLC (mediana całkowitego przeżycia 17 vs 7,0 miesięcy, P 0,0001).⁷

Przyczyny zgonów

Śmierć u pacjentów z paraneoplastycznymi zespołami nerwowymi najczęściej następuje z powodu:⁸⁹

Progresji choroby nowotworowej – stanowi najczęstszą przyczynę zgonu
Nieodwracalnego uszkodzenia układu, najczęściej ostrej niewydolności serca lub nerek

Wpływ leczenia na rokowanie

Leczenie zarówno nowotworu podstawowego, jak i terapia immunomodulująca mogą zapobiec dalszym uszkodzeniom układu nerwowego i poprawić objawy oraz jakość życia. Wśród pacjentów otrzymujących immunoterapię w leczeniu paraneoplastycznych zespołów nerwowych (75% przypadków), steroidy stanowią część postępowania terapeutycznego u 78% chorych.¹⁰¹¹

Warto podkreślić, że w niektórych przypadkach uszkodzenie układu nerwowego może być odwracalne dzięki terapii ukierunkowanej na nowotwór i układ immunologiczny. Jednak czasami paraneoplastyczne zespoły nerwowe mogą prowadzić do trwałego uszkodzenia układu nerwowego.¹²

Jakość życia pacjentów

Długoterminowe obserwacje wskazują na znaczny spadek jakości życia u pacjentów z paraneoplastycznymi zespołami nerwowymi. Większość chorych zmaga się z istotną niepełnosprawnością i upośledzeniem funkcjonalnym w perspektywie długoterminowej.¹³

Niektóre zespoły paraneoplastyczne mogą ustąpić samoistnie, co również wpływa na zróżnicowanie rokowania w tej grupie pacjentów.¹⁴

Znaczenie wczesnej diagnostyki

Ze względu na fakt, że objawy paraneoplastycznych zespołów nerwowych są podobne do objawów wielu innych schorzeń, w tym samego nowotworu, powikłań nowotworowych i niektórych terapii przeciwnowotworowych, wczesna i dokładna diagnostyka ma kluczowe znaczenie dla rokowania.¹⁵¹⁶

Paraneoplastyczne zespoły nerwowe mogą być pierwszym lub najbardziej wyraźnym objawem nowotworu, co podkreśla znaczenie ich rozpoznania w kontekście wczesnego wykrywania choroby nowotworowej i potencjalnie lepszego rokowania.¹⁷

Kolejne rozdziały

Zapraszamy do dalszego czytania naszego leksykonu.

Wybierz kolejny rozdział z menu poniżej, aby otworzyć nową podstronę kompedium wiedzy i uzyskać szczegółowe informację o leku, substancji lub chorobie.

Materiały źródłowe

#1 Paraneoplastic syndromes of the nervous system – Symptoms and causes – Mayo Clinic
https://www.mayoclinic.org/diseases-conditions/paraneoplastic-syndromes/symptoms-causes/syc-20355687
Paraneoplastic syndromes of the nervous system are a group of rare conditions that develop in some people who have cancer. […] Paraneoplastic syndromes of the nervous system occur when cancer-fighting agents of the immune system also attack parts of the brain, spinal cord, peripheral nerves or muscle. […] Sometimes the injury to the nervous system can be reversed with therapy directed toward the cancer and the immune system. But sometimes paraneoplastic syndromes can result in permanent damage to the nervous system. […] Treating the cancer and other therapies may prevent further damage and improve symptoms and quality of life. […] Symptoms of paraneoplastic syndromes of the nervous system are similar to those of many conditions, including cancer, cancer complications and some cancer treatments.
#2 Paraneoplastic Syndromes: Practice Essentials, Pathophysiology, Etiology
https://emedicine.medscape.com/article/280744-overview
Paraneoplastic syndromes may be the first or most prominent manifestation of a cancer. […] Because paraneoplastic syndromes differ widely from individual to individual, prognosis may vary greatly. For example, disseminated intravascular coagulation indicates a poor prognosis, whereas hypertrophic osteoarthropathy is one of the few paraneoplastic syndromes that may indicate a more favorable prognosis. Some paraneoplastic disorders may resolve spontaneously. […] In a long-term study of quality of life and survival in patients with Lambert-Eaton myasthenic syndrome (LEMS), Lipka and colleagues reported that survival was significantly longer in patients with small cell lung cancer (SCLC) and LEMS than in those with SCLC alone (overall median survival 17 vs 7.0 months, P 0.0001). […] Death may result from the underlying cancer or from an irreversible system impairment, usually acute heart failure or kidney failure.
#3 Paraneoplastic Syndromes: Practice Essentials, Pathophysiology, Etiology
https://emedicine.medscape.com/article/280744-overview
Paraneoplastic syndromes may be the first or most prominent manifestation of a cancer. […] Because paraneoplastic syndromes differ widely from individual to individual, prognosis may vary greatly. For example, disseminated intravascular coagulation indicates a poor prognosis, whereas hypertrophic osteoarthropathy is one of the few paraneoplastic syndromes that may indicate a more favorable prognosis. Some paraneoplastic disorders may resolve spontaneously. […] In a long-term study of quality of life and survival in patients with Lambert-Eaton myasthenic syndrome (LEMS), Lipka and colleagues reported that survival was significantly longer in patients with small cell lung cancer (SCLC) and LEMS than in those with SCLC alone (overall median survival 17 vs 7.0 months, P 0.0001). […] Death may result from the underlying cancer or from an irreversible system impairment, usually acute heart failure or kidney failure.
#4 Paraneoplastic syndromes of the nervous system – Symptoms and causes – Mayo Clinic
https://www.mayoclinic.org/diseases-conditions/paraneoplastic-syndromes/symptoms-causes/syc-20355687
Early diagnosis and appropriate care are important for treating the cancer and preventing further damage of the nervous system. […] Researchers believe that paraneoplastic syndromes of the nervous system are caused by cancer-fighting abilities of the immune system. […] Instead of attacking only the cancer cells, these immune system agents also attack the healthy cells of the nervous system. […] Any cancer may be associated with a paraneoplastic syndrome of the nervous system. However, it occurs more often in people with cancers of the lung, ovary, breast, testis or lymphatic system.
#5 Long term survival and outcomes in patients with paraneoplastic neurologic syndromes – PubMed
https://pubmed.ncbi.nlm.nih.gov/39624101/
Objective: It is unknown whether delay in diagnosis affects morbidity reportedly in paraneoplastic syndromes (PNS). We aimed to explore various aspects of PNS, including prevalence, clinical characteristics, diagnostic criteria, and treatment outcomes. […] Among patients who received immunotherapy as n-PNS treatment (n=9, 75%), steroids were a part of the management at 78% (n=7). […] Death occurred in 9 of the 12 patients, with most cases deaths attributed to cancer progression. […] In up to 8 years of follow up, there was no difference in mortality among patients who presented initially n-PNS. There was a significant decline in the quality of life, most face substantial disability and functional impairment long term.
#6 Long term survival and outcomes in patients with paraneoplastic neurologic syndromes – PubMed
https://pubmed.ncbi.nlm.nih.gov/39624101/
Objective: It is unknown whether delay in diagnosis affects morbidity reportedly in paraneoplastic syndromes (PNS). We aimed to explore various aspects of PNS, including prevalence, clinical characteristics, diagnostic criteria, and treatment outcomes. […] Among patients who received immunotherapy as n-PNS treatment (n=9, 75%), steroids were a part of the management at 78% (n=7). […] Death occurred in 9 of the 12 patients, with most cases deaths attributed to cancer progression. […] In up to 8 years of follow up, there was no difference in mortality among patients who presented initially n-PNS. There was a significant decline in the quality of life, most face substantial disability and functional impairment long term.
#7 Paraneoplastic Syndromes: Practice Essentials, Pathophysiology, Etiology
https://emedicine.medscape.com/article/280744-overview
Paraneoplastic syndromes may be the first or most prominent manifestation of a cancer. […] Because paraneoplastic syndromes differ widely from individual to individual, prognosis may vary greatly. For example, disseminated intravascular coagulation indicates a poor prognosis, whereas hypertrophic osteoarthropathy is one of the few paraneoplastic syndromes that may indicate a more favorable prognosis. Some paraneoplastic disorders may resolve spontaneously. […] In a long-term study of quality of life and survival in patients with Lambert-Eaton myasthenic syndrome (LEMS), Lipka and colleagues reported that survival was significantly longer in patients with small cell lung cancer (SCLC) and LEMS than in those with SCLC alone (overall median survival 17 vs 7.0 months, P 0.0001). […] Death may result from the underlying cancer or from an irreversible system impairment, usually acute heart failure or kidney failure.
#8 Paraneoplastic Syndromes: Practice Essentials, Pathophysiology, Etiology
https://emedicine.medscape.com/article/280744-overview
Paraneoplastic syndromes may be the first or most prominent manifestation of a cancer. […] Because paraneoplastic syndromes differ widely from individual to individual, prognosis may vary greatly. For example, disseminated intravascular coagulation indicates a poor prognosis, whereas hypertrophic osteoarthropathy is one of the few paraneoplastic syndromes that may indicate a more favorable prognosis. Some paraneoplastic disorders may resolve spontaneously. […] In a long-term study of quality of life and survival in patients with Lambert-Eaton myasthenic syndrome (LEMS), Lipka and colleagues reported that survival was significantly longer in patients with small cell lung cancer (SCLC) and LEMS than in those with SCLC alone (overall median survival 17 vs 7.0 months, P 0.0001). […] Death may result from the underlying cancer or from an irreversible system impairment, usually acute heart failure or kidney failure.
#9 Long term survival and outcomes in patients with paraneoplastic neurologic syndromes – PubMed
https://pubmed.ncbi.nlm.nih.gov/39624101/
Objective: It is unknown whether delay in diagnosis affects morbidity reportedly in paraneoplastic syndromes (PNS). We aimed to explore various aspects of PNS, including prevalence, clinical characteristics, diagnostic criteria, and treatment outcomes. […] Among patients who received immunotherapy as n-PNS treatment (n=9, 75%), steroids were a part of the management at 78% (n=7). […] Death occurred in 9 of the 12 patients, with most cases deaths attributed to cancer progression. […] In up to 8 years of follow up, there was no difference in mortality among patients who presented initially n-PNS. There was a significant decline in the quality of life, most face substantial disability and functional impairment long term.
#10 Paraneoplastic syndromes of the nervous system – Symptoms and causes – Mayo Clinic
https://www.mayoclinic.org/diseases-conditions/paraneoplastic-syndromes/symptoms-causes/syc-20355687
Paraneoplastic syndromes of the nervous system are a group of rare conditions that develop in some people who have cancer. […] Paraneoplastic syndromes of the nervous system occur when cancer-fighting agents of the immune system also attack parts of the brain, spinal cord, peripheral nerves or muscle. […] Sometimes the injury to the nervous system can be reversed with therapy directed toward the cancer and the immune system. But sometimes paraneoplastic syndromes can result in permanent damage to the nervous system. […] Treating the cancer and other therapies may prevent further damage and improve symptoms and quality of life. […] Symptoms of paraneoplastic syndromes of the nervous system are similar to those of many conditions, including cancer, cancer complications and some cancer treatments.
#11 Long term survival and outcomes in patients with paraneoplastic neurologic syndromes – PubMed
https://pubmed.ncbi.nlm.nih.gov/39624101/
Objective: It is unknown whether delay in diagnosis affects morbidity reportedly in paraneoplastic syndromes (PNS). We aimed to explore various aspects of PNS, including prevalence, clinical characteristics, diagnostic criteria, and treatment outcomes. […] Among patients who received immunotherapy as n-PNS treatment (n=9, 75%), steroids were a part of the management at 78% (n=7). […] Death occurred in 9 of the 12 patients, with most cases deaths attributed to cancer progression. […] In up to 8 years of follow up, there was no difference in mortality among patients who presented initially n-PNS. There was a significant decline in the quality of life, most face substantial disability and functional impairment long term.
#12 Paraneoplastic syndromes of the nervous system – Symptoms and causes – Mayo Clinic
https://www.mayoclinic.org/diseases-conditions/paraneoplastic-syndromes/symptoms-causes/syc-20355687
Paraneoplastic syndromes of the nervous system are a group of rare conditions that develop in some people who have cancer. […] Paraneoplastic syndromes of the nervous system occur when cancer-fighting agents of the immune system also attack parts of the brain, spinal cord, peripheral nerves or muscle. […] Sometimes the injury to the nervous system can be reversed with therapy directed toward the cancer and the immune system. But sometimes paraneoplastic syndromes can result in permanent damage to the nervous system. […] Treating the cancer and other therapies may prevent further damage and improve symptoms and quality of life. […] Symptoms of paraneoplastic syndromes of the nervous system are similar to those of many conditions, including cancer, cancer complications and some cancer treatments.
#13 Long term survival and outcomes in patients with paraneoplastic neurologic syndromes – PubMed
https://pubmed.ncbi.nlm.nih.gov/39624101/
Objective: It is unknown whether delay in diagnosis affects morbidity reportedly in paraneoplastic syndromes (PNS). We aimed to explore various aspects of PNS, including prevalence, clinical characteristics, diagnostic criteria, and treatment outcomes. […] Among patients who received immunotherapy as n-PNS treatment (n=9, 75%), steroids were a part of the management at 78% (n=7). […] Death occurred in 9 of the 12 patients, with most cases deaths attributed to cancer progression. […] In up to 8 years of follow up, there was no difference in mortality among patients who presented initially n-PNS. There was a significant decline in the quality of life, most face substantial disability and functional impairment long term.
#14 Paraneoplastic Syndromes: Practice Essentials, Pathophysiology, Etiology
https://emedicine.medscape.com/article/280744-overview
Paraneoplastic syndromes may be the first or most prominent manifestation of a cancer. […] Because paraneoplastic syndromes differ widely from individual to individual, prognosis may vary greatly. For example, disseminated intravascular coagulation indicates a poor prognosis, whereas hypertrophic osteoarthropathy is one of the few paraneoplastic syndromes that may indicate a more favorable prognosis. Some paraneoplastic disorders may resolve spontaneously. […] In a long-term study of quality of life and survival in patients with Lambert-Eaton myasthenic syndrome (LEMS), Lipka and colleagues reported that survival was significantly longer in patients with small cell lung cancer (SCLC) and LEMS than in those with SCLC alone (overall median survival 17 vs 7.0 months, P 0.0001). […] Death may result from the underlying cancer or from an irreversible system impairment, usually acute heart failure or kidney failure.
#15 Paraneoplastic syndromes of the nervous system – Symptoms and causes – Mayo Clinic
https://www.mayoclinic.org/diseases-conditions/paraneoplastic-syndromes/symptoms-causes/syc-20355687
Paraneoplastic syndromes of the nervous system are a group of rare conditions that develop in some people who have cancer. […] Paraneoplastic syndromes of the nervous system occur when cancer-fighting agents of the immune system also attack parts of the brain, spinal cord, peripheral nerves or muscle. […] Sometimes the injury to the nervous system can be reversed with therapy directed toward the cancer and the immune system. But sometimes paraneoplastic syndromes can result in permanent damage to the nervous system. […] Treating the cancer and other therapies may prevent further damage and improve symptoms and quality of life. […] Symptoms of paraneoplastic syndromes of the nervous system are similar to those of many conditions, including cancer, cancer complications and some cancer treatments.
#16 Paraneoplastic syndromes of the nervous system – Symptoms and causes – Mayo Clinic
https://www.mayoclinic.org/diseases-conditions/paraneoplastic-syndromes/symptoms-causes/syc-20355687
Early diagnosis and appropriate care are important for treating the cancer and preventing further damage of the nervous system. […] Researchers believe that paraneoplastic syndromes of the nervous system are caused by cancer-fighting abilities of the immune system. […] Instead of attacking only the cancer cells, these immune system agents also attack the healthy cells of the nervous system. […] Any cancer may be associated with a paraneoplastic syndrome of the nervous system. However, it occurs more often in people with cancers of the lung, ovary, breast, testis or lymphatic system.
#17 Paraneoplastic Syndromes: Practice Essentials, Pathophysiology, Etiology
https://emedicine.medscape.com/article/280744-overview
Paraneoplastic syndromes may be the first or most prominent manifestation of a cancer. […] Because paraneoplastic syndromes differ widely from individual to individual, prognosis may vary greatly. For example, disseminated intravascular coagulation indicates a poor prognosis, whereas hypertrophic osteoarthropathy is one of the few paraneoplastic syndromes that may indicate a more favorable prognosis. Some paraneoplastic disorders may resolve spontaneously. […] In a long-term study of quality of life and survival in patients with Lambert-Eaton myasthenic syndrome (LEMS), Lipka and colleagues reported that survival was significantly longer in patients with small cell lung cancer (SCLC) and LEMS than in those with SCLC alone (overall median survival 17 vs 7.0 months, P 0.0001). […] Death may result from the underlying cancer or from an irreversible system impairment, usually acute heart failure or kidney failure.